CD24.28.1XX.NFkBIAm CAR T cells

CD24.28.1XX.NFkBIAm CAR T cells are an experimental, preclinical-stage chimeric antigen receptor (CAR) T cell therapy designed to target the CD24 antigen, which is frequently overexpressed in hematologic malignancies such as acute lymphoblastic leukemia (ALL), lymphoma, and acute myeloid leukemia (AML). Developed by researchers at Memorial Sloan Kettering Cancer Center, this construct utilizes a CD28 costimulatory domain and a modified CD3ζ signaling domain (1XX) to enhance potency. To mitigate the severe on-target, off-tumor toxicities—specifically cytokine release syndrome (CRS) and pulmonary pathology—associated with CD24-targeted therapies, the cells are engineered to overexpress a degradation-resistant form of IκBα (NFkBIAm). This inhibitor attenuates the canonical NF-κB pathway, reducing systemic cytokine production. While NFkBIAm can impede tumor clearance, the research explores the co-expression of switch receptors (e.g., PD-1–OX40 or Fas–4-1BB) to transiently restore NF-κB activation and maintain anti-leukemic efficacy.

Other names

CD24.28.1XX.NFkBIAm CAR T cellsCD-24.28.1XX.NFkBIAm CAR T cellsCD 24.28.1XX.NFkBIAm CAR T cells